Dahut WL - Search Results

1

Androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL. Sharifi N, et al. Among authors: dahut wl. JAMA. 2005 Jul 13;294(2):238-44. doi: 10.1001/jama.294.2.238. JAMA. 2005. PMID: 16014598 Review.

2

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

3

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Among authors: dahut wl. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

4

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

5

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Among authors: dahut wl. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

6

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Behrens RJ, Gulley JL, Dahut WL. Behrens RJ, et al. Among authors: dahut wl. Am J Ther. 2003 May-Jun;10(3):228-32. doi: 10.1097/00045391-200305000-00011. Am J Ther. 2003. PMID: 12756431

7

A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.

Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E. Hamilton M, et al. Acta Oncol. 2003;42(3):195-201. doi: 10.1080/02841860310010718. Acta Oncol. 2003. PMID: 12852695 Clinical Trial.

8

The emerging role of bisphosphonates in prostate cancer.

Posadas EM, Dahut WL, Gulley J. Posadas EM, et al. Among authors: dahut wl. Am J Ther. 2004 Jan-Feb;11(1):60-73. doi: 10.1097/00045391-200401000-00012. Am J Ther. 2004. PMID: 14704597 Review.

9

Novel therapeutic strategies in prostate cancer.

Retter AS, Gulley JL, Dahut WL. Retter AS, et al. Among authors: dahut wl. Cancer Biol Ther. 2004 Apr;3(4):371-6. doi: 10.4161/cbt.3.4.725. Epub 2004 Apr 29. Cancer Biol Ther. 2004. PMID: 14726702 Review.

10

Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.

Gulley J, Dahut WL. Gulley J, et al. Among authors: dahut wl. Urology. 2003 Dec 29;62 Suppl 1:147-54. doi: 10.1016/j.urology.2003.08.003. Urology. 2003. PMID: 14747053 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page